What Mitabor Treats: Main Uses and Benefits

Mitabor is primarily applied in the management of Major Depressive Disorder (MDD) in adults. It is relevant in contexts where additional symptomatic support is needed, especially when the condition presents with disruptive features.

The medication is commonly used to help manage the core affective symptoms of depression, including persistent sadness, feelings of worthlessness, and loss of interest. Mitabor also provides supportive relief for two common co-occurring issues: sleep disruption (insomnia) and poor appetite. This approach contributes to easing the overall symptom load and supports patients during difficult episodes by easing distress.

“It is commonly used when short-term symptomatic assistance is needed for core mood symptoms and associated physical discomforts.”

The therapeutic support offered is particularly relevant when patients experience symptoms related to systemic imbalance, such as appetite loss, making it relevant for patient groups like older adults who frequently experience associated poor appetite.

Quick Fact: Supportive Relief for Symptoms of Appetite and Sleep Deficits

---

Regulatory References

1. DailyMed (NIH) information on Mirtazapine

Who Can and Cannot Use Mitabor (Mirtazapine) — Official Regulatory Information

Category	Official Regulatory Status
Populations for whom use is allowed (as stated in label)	Adults with Major Depressive Disorder (MDD).
Populations for whom use is not recommended (if applicable)	Children and adolescents under the age of 18 years.
Populations for whom use is contraindicated	Patients with known hypersensitivity to mirtazapine; patients taking or recently stopping MAOIs (Monoamine Oxidase Inhibitors).
Age-related eligibility rules	Pediatric: Safety and effectiveness have not been established. Geriatric: Use requires caution due to reduced clearance.
Condition-specific eligibility rules	Renal/Hepatic Impairment: Use requires caution in moderate to severe impairment; clearance is reduced.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Use only if clearly needed. Lactation: Caution should be exercised when administered to a nursing woman.
Eligibility-related restrictions	Use requires caution in patients with a history of seizure disorder or epilepsy. Orally Disintegrating Tablets contain phenylalanine (relevant for PKU).

---

Eligibility Classifications (High-Level)

Classification	Official Regulatory Wording
Eligibility severity classification (as defined in official documents)	Contraindicated; Not approved; Caution is indicated.
Regulatory basis	FDA Prescribing Information; EMA Summary of Product Characteristics (SmPC).
Eligibility-context constraints (as defined in official documents)	Contraindications; Use in Specific Populations; Special Warnings and Precautions.

---

Resulting Eligibility Structure

Official eligibility statements:

• Mitabor is contraindicated in patients with a known hypersensitivity or concurrent use of a Monoamine Oxidase Inhibitor (MAOI).
• The medicine is not approved for the pediatric population as safety and effectiveness have not been established.
• Use requires caution in the elderly and in patients with moderate to severe renal or hepatic impairment.

Regulatory documents establish that Mitabor is solely indicated for adults, while establishing absolute prohibitions (contraindications) and mandating caution or conditional use for populations with impaired organ function (kidney/liver) or certain medical histories, such as a history of seizures or known hypersensitivity. This structure strictly limits eligibility based on medical history, current concomitant treatment, and physiological status.

Interactions with other medicines and products

Mitabor (Mirtazapine) has officially documented interaction patterns that are classified based on the resulting regulatory constraint or effect on drug exposure, as stipulated in government labeling.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, is strictly contraindicated. A mandatory 14-day washout period must elapse between discontinuing an MAOI and starting Mitabor, or vice-versa.

Exposure-Altering Metabolic Interactions

Mitabor exposure is susceptible to co-administered substances that affect its metabolic clearance. Strong CYP3A Inducers (e.g., carbamazepine) officially decrease Mirtazapine plasma concentrations. Conversely, Strong CYP3A Inhibitors (e.g., ketoconazole) and Cimetidine officially increase Mirtazapine concentrations, a pharmacokinetic pattern that may require clinical management.

Risk of Additive Effect Interactions

Combining Mitabor with other serotonergic drugs (e.g., triptans, SSRIs) or the herbal product St. John's Wort is documented to increase the risk of Serotonin Syndrome. Additionally, co-administration with alcohol and other Central Nervous System (CNS) depressants has documented additive sedative effects.

Other Documented Constraints

The official label requires monitoring of INR (International Normalized Ratio) during co-administration with the anticoagulant warfarin. Furthermore, hepatic and renal impairment are officially associated with a documented reduced clearance of Mitabor, indicating a state of increased exposure in these specific populations.

Dual Action on Norepinephrine and Serotonin Signaling

The core mechanism of Mitabor involves simultaneous antagonism of presynaptic alpha2-adrenergic receptors, functionally removing the negative feedback mechanism on the release of both Norepinephrine and Serotonin (5 -HT). This enhanced release is coupled with the blockade of specific postsynaptic Serotonin receptors (5 -HT2 and 5 -HT3), which selectively channels the increased 5 -HT signal to the 5 -HT1 receptors. This coordinated approach results in an altered activity pattern in the central pathways governing emotional processing, generating the Noradrenergic and Specific Serotonergic Antidepressant (NaSSA) profile.

Central Histamine System Modulation

Mitabor exhibits high affinity for and acts as an antagonist at the Histamine H1 receptors within the central nervous system (CNS). This molecular interaction suppresses the Histaminergic pathway, which is a key component of the brain's ascending arousal system. The resultant reduction in central alertness generates a CNS depressant effect that is an inherent consequence of this specific receptor antagonism.

Secondary Pathway Modulation

The mechanism also involves antagonism of the 5 -HT3 receptors, which modulates visceral signaling and acts on centers related to emesis, resulting in an altered physiological state of the gut-brain axis. Additionally, the moderate alpha1-adrenergic antagonism may influence peripheral vascular tone, impacting postural blood pressure regulation mechanisms.

How to Use Mitabor: Official Administration Guidelines

Mitabor (Mirtazapine) is administered through the oral route using either standard film-coated tablets or Orally Disintegrating Tablets (SolTab) in strengths ranging from 15 mg to 45 mg. The official usage protocol centers on specific dosing, frequency, and administration rules to ensure standardized use.

---

Standard Dosing and Frequency

The treatment protocol specifies a starting dose for adults, which is typically 15 mg or 30 mg, taken once daily. The daily dose may be adjusted in increments after a minimum interval of one to two weeks to allow for clinical assessment, with the effective maintenance range being between 15 mg and 45 mg per day. The maximum recommended daily dose for adults is 45 mg. Mirtazapine is usually scheduled for once-daily intake, preferably in the evening before sleep, although the total dose may be divided into two smaller doses.

---

Administration Requirements and Duration

Standard tablets are swallowed whole with fluid, and intake is permitted with or without food. The Orally Disintegrating Tablet (SolTab) must be used immediately after peeling back the blister foil and is allowed to dissolve on the tongue without water. The duration of therapy should continue for at least four to six months after the disappearance of symptoms. If discontinuation is necessary, the dose must be gradually reduced over a period of time. In cases of renal or hepatic impairment, a dose reduction may be necessary due to decreased clearance. If a dose is missed, patients must not compensate by taking two doses at the same time.

Research evidence / Overview of studies for Mitabor

Research Evidence for Major Depressive Disorder (MDD)

Mitabor was evaluated in research exploring Major Depressive Disorder (MDD) in adults. The main body of research consists of numerous short-term Randomized Controlled Trials (RCTs) designed to compare the study medication against an inactive substance (placebo) or other established treatments. These RCTs are relevant in trials assessing short-term or episodic symptom patterns. In addition to individual trials, the evidence was studied for systematic review and meta-analysis.

In these trials, researchers monitored changes in the outcomes related to systemic or functional imbalance, specifically using standardized scales to measure the intensity of core symptoms. Short-term studies reported how symptoms evolved in the observed populations; the measured changes in symptom scores were observed to differ between the study drug group and the placebo group. The majority of studies focused on episodes where symptoms become more noticeable; consequently, evidence remains limited to the short-term course of MDD, typically over 4 to 8 weeks.

---

Research Findings on Associated Symptoms

In addition to core depression symptoms, research explored Mitabor in relation to outcomes related to physical discomfort, which may include difficulty sleeping and changes in appetite.

Examining the Research on Sleep Disturbance

Research was studied for outcomes related to sleep difficulties (insomnia) often present in individuals with MDD. The data related to this specific symptom was largely derived from settings with varying symptom burdens, often being assessed as a secondary measurement within the main MDD clinical trials. Dedicated sleep studies using objective monitoring techniques was observed in some studies to look at changes in sleep architecture, such as total sleep time. The evidence is limited to the acute management of the sleep component of MDD.

Examining the Research on Appetite and Weight Changes

Mitabor was studied for outcomes related to changes in appetite and body weight. In the acute clinical trials, researchers monitored these changes as a part of the study’s protocol, often recording them as specific secondary outcomes. Data show patterns related to measured shifts in appetite and body weight was observed in the populations studied. Because the data is mainly derived from monitoring body weight as a measurable event in MDD trials, rather than from trials designed specifically to examine appetite outcomes, controlled research is less prevalent.

---

What Research Gaps and Uncertainties Remain

Research on Mitabor contributes to understanding symptom patterns but also highlights where the evidence has limitations. One of the main gaps is that most high-quality, placebo-controlled trials follow-up durations were limited to acute treatment periods (typically 4–8 weeks), so controlled research exploring outcomes over several years is limited. Furthermore, while data show patterns related to changes in sleep and appetite, the evidence quality varies across studies when compared to the core depression symptom measurements. Research does not determine whether an individual will respond similarly, and these study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.
2. Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men (ClinicalTrials.gov NCT00878540)

Common questions about Mitabor (FAQ)

Q: What are the most common side effects of Mitabor?

According to the official product information, the most frequently reported adverse effects in clinical trials—classified as 'Very Common' (potentially affecting more than 1 in 10 people)—included dry mouth, increased appetite, weight gain, and somnolence (drowsiness). This frequency data is derived from the observation of effects in controlled studies.

---

Q: How does Mitabor make you feel sleepy?

Studies and official information indicate that Mitabor acts as a potent antagonist at the Histamine H1 receptors. This action against the central histamine system is the documented pharmacological basis associated with the medicine’s sedative properties.

---

Q: What is Serotonin Syndrome and how is it related to Mitabor?

Serotonin Syndrome is a potentially serious condition caused by high levels of serotonin in the body, which can result in symptoms like agitation, confusion, sweating, and rapid heart rate. Official labeling for Mitabor carries a warning about the increased risk of Serotonin Syndrome when the drug is used in combination with other serotonergic medicines (drugs that also affect serotonin levels).

---

Q: Can I drink alcohol while I’m taking Mitabor?

Regulatory documents state that consuming alcohol while taking this medicine should be avoided due to the documented interaction risk. The combination can lead to additive sedative effects, potentially intensifying nervous system side effects such as dizziness, drowsiness, and difficulty concentrating.

---

Q: How long does it typically take for Mitabor to start working for depression?

The effectiveness of this medicine for Major Depressive Disorder was established in short-term, typically six-week controlled clinical trials. The onset of noticeable therapeutic changes or full benefits can vary significantly, as individual response rates differ.

---

Q: Is Mitabor a controlled substance?

According to official regulatory listings, the active ingredient in Mitabor (mirtazapine) is not classified as a controlled substance under the U.S. Controlled Substances Act (DEA Schedule) or equivalent international frameworks.

---

Q: How should I dispose of Mitabor if I cannot find a take-back program?

If a medicine take-back program is unavailable, official regulatory guidelines recommend discarding many non-controlled medicines, including Mitabor, in household trash. To help prevent accidental ingestion or misuse, the recommended procedure involves mixing the medicine with an undesirable substance (such as used coffee grounds or cat litter), placing the mixture in a sealed container, and then discarding it in the trash. Never flush the medicine.

---

Q: Does Mitabor affect blood sugar levels?

The official product labeling reports adverse reactions related to changes in metabolism, such as elevations in cholesterol and triglyceride levels (hyperlipidemia) and low sodium (hyponatremia). However, the label does not explicitly state effects on blood sugar (glucose) levels.

---

Q: What is the difference between the standard tablet and the SolTab?

Both the standard tablet and the Orally Disintegrating Tablet (SolTab) forms of Mitabor are considered bioequivalent, meaning they deliver the same amount of medicine to the body. The standard tablet is swallowed whole with water, while the SolTab is designed to dissolve on the tongue without needing water, providing flexibility for administration.

How to Store and Dispose of Mitabor?

Mitabor (Mirtazapine) must be stored at controlled room temperature (68 to 77 F or 20 to 25 C), protected from high moisture and direct light. The medicine must be kept in its tightly closed, original container and must not be frozen.

Orally Disintegrating Tablets (ODT) require strict handling; they must remain in the blister pack until administration and must be used immediately upon removal.

For safety, Mitabor must be stored out of the sight and reach of children in a secure, up-and-away location. Unused or expired medication should be discarded through a medicine take-back program. Regulatory guidance instructs against disposing of Mitabor via wastewater to protect the environment.